SynGenSys specializes in the development of synthetic genetic systems aimed at enhancing the efficacy and safety of next-generation biomedicines. Their technology suite includes the Lexicon, which comprises curated libraries of genetic components such as synthetic promoters and signal peptides, facilitating rapid testing and application-specific customization. The Syntax platform allows for the computational extraction of valuable genetic information from extensive genomic datasets, enabling the design of novel synthetic genetic components tailored to specific user-defined processes. Additionally, the SGS Express technology provides rapid testing of genetic components and synthetic assemblies in model systems, ensuring comparative functional validation to refine synthetic genetic designs.

The company offers a range of products and services that cater to various biomedical applications, including cell and gene therapies, mRNA vaccines, and biopharmaceutical manufacturing. Their Synthetic Expression Technologies (SETs) are designed to optimize recombinant protein production and improve the stability and efficiency of gene expression. SynGenSys emphasizes the importance of precision control in gene therapies, providing customizable solutions that target specific cell types and enhance therapeutic outcomes. By leveraging their deep biological knowledge and innovative tools, SynGenSys aims to accelerate the delivery of safer and more effective medicines to the clinic.

United Kingdom

SynGenSys creates product-specific libraries of synthetic genetic parts for next-generation biomedicines and biomanufacturing processes. 

Our philosophy is simple: all products and production processes are unique. Therefore core genetic assemblies used for therapy or biomanufacturing should harbour custom synthetic DNA parts and circuits designed to be fit for a specific purpose.

SynGenSys

Company Details